{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T01:57:10Z","timestamp":1777514230477,"version":"3.51.4"},"reference-count":27,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte Corporation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Cutan Med Surg"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Vitiligo is an autoimmune disease resulting in skin depigmentation. Treatment options are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To examine disease burden and healthcare resource utilization (HCRU) among patients with vitiligo in Qu\u00e9bec, Canada.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      In this retrospective study, data were obtained from the R\u00e9gie de l\u2019Assurance Maladie du Qu\u00e9bec (RAMQ) databases for 125,000 random individuals from January 2010 to December 2019. The\n                      <jats:italic toggle=\"yes\">International Classification of Diseases, Ninth Revision<\/jats:italic>\n                      (\n                      <jats:italic toggle=\"yes\">ICD-9<\/jats:italic>\n                      ) diagnostic code [709.x (other skin disorders)] with vitiligo-related treatment was used to identify patients with vitiligo. Patient characteristics and treatments, including treatment type, episodes (treatments used without discontinuation), and sequences (treatment episodes \u226530 days), were assessed. Annualized HCRU and costs (2021 adjusted) included all-cause hospitalization, emergency department visits, outpatient visits, and medications among patients with vitiligo (n = 113) and age- and sex-matched non-vitiligo controls (n = 339).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Of patients with vitiligo (mean age, 50.0 years; 68.1% female) identified using\n                      <jats:italic toggle=\"yes\">ICD-9<\/jats:italic>\n                      code 709.x with vitiligo-related treatment, 36.3% received \u22654 treatment episodes. Treatment patterns were heterogeneous, with 43 different sequences reported. Annualized mean outpatient visits (16.1 vs 5.5) and all-cause outpatient service costs per patient were significantly higher in the vitiligo versus the control group (CAN$1037 vs CAN$523;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .01). Total all-cause services costs were higher for patients with vitiligo in the year after versus before diagnosis (CAN$3679 vs CAN$2085;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .04).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      Vitiligo is associated with significant burden and HCRU among patients in Qu\u00e9bec, Canada, who were identified by\n                      <jats:italic toggle=\"yes\">ICD-9<\/jats:italic>\n                      code 709.x plus vitiligo-related treatment. Measurement of true vitiligo burden remains challenging.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/12034754241304683","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:02:24Z","timestamp":1737590544000},"page":"234-242","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Burden of Vitiligo in Canada: Retrospective Analysis of a Canadian Public Claims Database"],"prefix":"10.1177","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6773-4645","authenticated-orcid":false,"given":"Julien","family":"Ringuet","sequence":"first","affiliation":[{"name":"Centre de Recherche Dermatologique du Qu\u00e9bec M\u00e9tropolitain, Qu\u00e9bec City, QC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace K.","family":"Wong","sequence":"additional","affiliation":[{"name":"Incyte Biosciences Canada Corporation, Pointe-Claire, QC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00e9ronique","family":"Baribeau","sequence":"additional","affiliation":[{"name":"PeriPharm Inc, Montr\u00e9al, QC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunil","family":"Kalia","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Skin Science and Photomedicine Institute, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9e","family":"Brisebois","sequence":"additional","affiliation":[{"name":"Incyte Biosciences Canada Corporation, Pointe-Claire, QC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0791-2518","authenticated-orcid":false,"given":"Jean","family":"Lachaine","sequence":"additional","affiliation":[{"name":"PeriPharm Inc, Montr\u00e9al, QC, Canada"},{"name":"Faculty of Pharmacy, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,1,22]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1159\/000506103"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2009.03765.x"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.08.063"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.07.036"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00631-6"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15255"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18129"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18257"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19450"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20596"},{"key":"e_1_3_3_12_2","unstructured":"Incyte Corporation. Opzelura (ruxolitinib cream). Full Prescribing Information. 2024."},{"key":"e_1_3_3_13_2","unstructured":"Incyte Corporation and Innomar Strategies Inc. Opzelura (ruxolitinib cream). Product Monograph. 2024."},{"key":"e_1_3_3_14_2","unstructured":"Incyte Biosciences Distribution BV. Opzelura (ruxolitinib cream). Summary of product characteristics. 2023."},{"key":"e_1_3_3_15_2","unstructured":"Incyte Biosciences U.K. Ltd. Opzelura (ruxolitinib cream). Summary of product characteristics. 2023."},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2011.05377.x"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.07.039"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-018652"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad245"},{"key":"e_1_3_3_20_2","unstructured":"R\u00e9gie de l\u2019Assurance Maladie du Qu\u00e9bec. Rapport Annuel de Gestion 2020-2021. 2022. Accessed October 2 2023. https:\/\/www.ramq.gouv.qc.ca\/fr\/media\/14201"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-022-02383-7"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"e_1_3_3_23_2","unstructured":"Statistics Canada. Table 18-10-0005-01 Consumer Price Index annual average not seasonally adjusted. 2023. Accessed October 2 2023. https:\/\/doi.org\/10.25318\/1810000501-eng"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-01001-2"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.05.048"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2023.08.025"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.3310\/hta24640"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.986918"}],"updated-by":[{"DOI":"10.1177\/12034754251322637","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000}}],"container-title":["Journal of Cutaneous Medicine and Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/12034754241304683","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/12034754241304683","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/12034754241304683","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:51:26Z","timestamp":1777391486000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/12034754241304683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,22]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1177\/12034754241304683"],"URL":"https:\/\/doi.org\/10.1177\/12034754241304683","relation":{},"ISSN":["1203-4754","1615-7109"],"issn-type":[{"value":"1203-4754","type":"print"},{"value":"1615-7109","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,22]]}}}